Arovella Therapeutics Ltd has released a press release.
Company Update - Letter to Shareholders
Filed with ASX ·
6ix hasn’t read this filing yet.
Arovella Therapeutics Limited on 6ix
Earlier from Arovella Therapeutics
- Prospectus - Placement
- Ordesa Feasibility Study Update
- Placement Offer to raise $2.76m
- AGM FY20 Chairmans address and virtual meeting guide
- AGM FY20 Presentation
Later from Arovella Therapeutics
- Zelira Therapeutics Feasibility Study Update
- Appendix 4D & Interim Financial Half Year Report FY2021
- Anagrelide Project Update
- Investor Presentation March 2021
- SUDA Licenses a Novel iNKT Cell Therapy Platform
Follow Arovella Therapeutics into a list and get an email when it puts out news.
Follow Arovella Therapeutics